301 results on '"Alpaugh, R. Katherine"'
Search Results
2. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
3. A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
4. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms
5. Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing
6. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
7. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
8. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial
9. Normal Variants and Pitfalls Encountered in PET Assessment of Gynecologic Malignancies
10. Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer
11. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer
12. Figure S7 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
13. Data from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
14. Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
15. Abstract 304: Micronuclei in circulating stromal cells correlates with PD-L1 expression and predicts progression in metastatic breast cancer
16. Supplementary Figures and tables from Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions
17. Data from Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions
18. A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
19. A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).
20. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer
21. Cancer Associated Macrophage-like Cells Are Prognostic for Highly Aggressive Prostate Cancer in Both the Non-Metastatic and Metastatic Settings.
22. Tracking changes in circulating stromal cells and circulating tumor cells predicts responsiveness of new line induction in metastatic breast cancer after 1 cycle of therapy.
23. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
24. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
25. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
26. A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.
27. Abstract P1-24-02: Genetic variants and tumor microenvironment in inflammatory breast cancer: Clues for targeted therapies
28. Biodistribution and Radiation Dosimetry of the Carbonic Anhydrase IX Imaging Agent [18 F]VM4-037 Determined from PET/CT Scans in Healthy Volunteers
29. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
30. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
31. Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis
32. Hyper engorged cancer associated macrophage-like cells in circulation predict for multi-organ metastatic disease in solid tumors.
33. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
34. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
35. A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.
36. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer
37. Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma
38. Production and characterization of mice transgenic for the A and B isoforms of human FcγRIII
39. Abstract B29: Use of deep sequencing of urinary DNA as a biomarker of residual disease status at the time of radical cystectomy
40. Circulating stromal cells as a potential blood-based biomarker for screening invasive solid tumors.
41. Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer
42. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon
43. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment
44. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fcγ RIII
45. Individualized Patient Dosing in Phase I Clinical Trials: The Role of Escalation With Overdose Control in PNU-214936
46. Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
47. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins
48. Abstract SY05-03: Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology
49. Real-time monitoring of circulating stromal cells in the blood to predict responsiveness of new-line therapies in metastatic breast cancer.
50. Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.